LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 1696

Search options

  1. Article ; Online: Impact of Cusp Repair on Reoperation Risk After the David Procedure.

    Settepani, Fabrizio / Cappai, Antioco / Basciu, Alessio / Barbone, Alessandro / Moz, Monica / Citterio, Enrico / Ornaghi, Diego / Tarelli, Giuseppe

    The Annals of thoracic surgery

    2016  Volume 102, Issue 5, Page(s) 1503–1511

    Abstract: ... 157 consecutive patients underwent valve-sparing aortic root replacement with the David technique ...

    Abstract Background: We assessed whether additional cusp repair during valve-sparing aortic root replacement affects the echocardiographic mid-term results; a subgroup analysis among patients with bicuspid aortic valve (BAV) and tricuspid aortic valve (TAV) was performed.
    Methods: Between June 2002 and May 2015, 157 consecutive patients underwent valve-sparing aortic root replacement with the David technique. Thirty patients (19%) had BAV. In 19 patients (12%), cusp motion or anatomic abnormalities contributed in determining aortic regurgitation requiring an additional cusp repair. Mean follow-up was 7 ± 3.4 years.
    Results: The cumulative 1-, 5-, and 12-year survival rates were 98%, 94%, and 90%, respectively. Fourteen patients (9%) required aortic valve replacement during follow-up. In 2 patients the underlying cause was bacterial endocarditis. Freedom from aortic valve reoperation was 96% at 1 year, 92% at 5 years, and 89% at 12 years. Reoperation rate was significantly higher (p < 0.001) in patients who received leaflet repair compared with patients who did not, with a freedom from reoperation at 8 years of 58% versus 94%. Among patients with BAV, those who did not require cusp repair had a freedom from reoperation at 8 years of 94%, with a significant difference compared with patients who received cusp repair (p = 0.04). Cusp repair did not affect reoperation risk in patients with tricuspid aortic valve.
    Conclusions: Adjunctive cusp repair seems to affect the mid-term reoperation risk in patients with BAV and not in patients with tricuspid aortic valve. We recommend caution in using this technique in case of asymmetric BAV requiring cusp repair.
    MeSH term(s) Adult ; Aorta/surgery ; Aortic Aneurysm/surgery ; Aortic Valve/abnormalities ; Aortic Valve/surgery ; Aortic Valve Insufficiency/surgery ; Bicuspid Aortic Valve Disease ; Blood Vessel Prosthesis Implantation/methods ; Calcinosis/epidemiology ; Calcinosis/etiology ; Calcinosis/surgery ; Endocarditis, Bacterial/etiology ; Endocarditis, Bacterial/surgery ; Female ; Follow-Up Studies ; Heart Valve Diseases/epidemiology ; Heart Valve Diseases/etiology ; Heart Valve Diseases/surgery ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Organ Sparing Treatments ; Postoperative Complications/epidemiology ; Postoperative Complications/etiology ; Postoperative Complications/surgery ; Reoperation/statistics & numerical data ; Retrospective Studies ; Risk
    Language English
    Publishing date 2016-07-14
    Publishing country Netherlands
    Document type Journal Article ; Video-Audio Media
    ZDB-ID 211007-6
    ISSN 1552-6259 ; 0003-4975
    ISSN (online) 1552-6259
    ISSN 0003-4975
    DOI 10.1016/j.athoracsur.2016.04.061
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Classics in Diabetes.

    D'Alessio, David

    Diabetes

    2023  Volume 72, Issue 9, Page(s) 1179

    Language English
    Publishing date 2023-08-21
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80085-5
    ISSN 1939-327X ; 0012-1797
    ISSN (online) 1939-327X
    ISSN 0012-1797
    DOI 10.2337/dbi23-0016
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Immunotherapy at all stages of hepatocellular carcinoma.

    Pinato, David J / Fulgenzi, Claudia A M / D'Alessio, Antonio

    Nature medicine

    2024  Volume 30, Issue 3, Page(s) 640–641

    MeSH term(s) Humans ; Carcinoma, Hepatocellular/therapy ; Liver Neoplasms/therapy ; Liver Neoplasms/pathology ; Immunotherapy
    Language English
    Publishing date 2024-02-26
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1220066-9
    ISSN 1546-170X ; 1078-8956
    ISSN (online) 1546-170X
    ISSN 1078-8956
    DOI 10.1038/s41591-024-02828-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Diabetes and Immune Checkpoint Inhibitors-Response.

    Cortellini, Alessio / D'Alessio, Antonio / Pinato, David J

    Clinical cancer research : an official journal of the American Association for Cancer Research

    2023  Volume 29, Issue 19, Page(s) 4017–4018

    MeSH term(s) Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Neoplasms/drug therapy ; Antibodies, Monoclonal/therapeutic use ; Diabetes Mellitus ; Immunotherapy
    Chemical Substances Immune Checkpoint Inhibitors ; Antibodies, Monoclonal
    Language English
    Publishing date 2023-10-01
    Publishing country United States
    Document type Research Support, Non-U.S. Gov't ; Letter ; Comment
    ZDB-ID 1225457-5
    ISSN 1557-3265 ; 1078-0432
    ISSN (online) 1557-3265
    ISSN 1078-0432
    DOI 10.1158/1078-0432.CCR-23-2097
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Glucagon as the First Incretin: Objects (in the Rearview Mirror) Are Closer Than They Appear.

    D'Alessio, David A / Marks, Vincent

    Diabetes

    2023  Volume 72, Issue 12, Page(s) 1739–1740

    MeSH term(s) Humans ; Diabetes Mellitus, Type 2/drug therapy ; Gastric Inhibitory Polypeptide ; Glucagon/pharmacology ; Incretins/pharmacology ; Insulin ; Blood Glucose/drug effects
    Chemical Substances Gastric Inhibitory Polypeptide (59392-49-3) ; Glucagon (9007-92-5) ; Incretins ; Insulin ; Blood Glucose
    Language English
    Publishing date 2023-11-20
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80085-5
    ISSN 1939-327X ; 0012-1797
    ISSN (online) 1939-327X
    ISSN 0012-1797
    DOI 10.2337/dbi26-0026
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Assessment of the incretin effect in healthy subjects: concordance between clamp and OGTT methods.

    Aulinger, Benedikt A / D'Alessio, David A

    American journal of physiology. Endocrinology and metabolism

    2023  Volume 325, Issue 4, Page(s) E412–E420

    Abstract: The incretin effect describes the insulin response to nutrient ingestion that exceeds the response to glycemia per se. It is mediated by gastrointestinal factors and is necessary to maintain postprandial glucose homeostasis. The incretin effect results ... ...

    Abstract The incretin effect describes the insulin response to nutrient ingestion that exceeds the response to glycemia per se. It is mediated by gastrointestinal factors and is necessary to maintain postprandial glucose homeostasis. The incretin effect results in a more than twofold increase of the insulin response to a meal in healthy people and two different techniques have been used in the past to measure its magnitude. Most studies employ an OGTT on 1 day, followed by a matching glucose infusion on a separate day. Another study design employs a hyperglycemic glucose clamp that is maintained after oral ingestion of glucose. Both protocols allow quantification of the incretin effect by comparing the insulin response to an identical glycemic stimulus. Here we performed a within-subject comparison of both techniques to quantify the incretin effect and suggest different calculation methods to interpret the results derived from the clamp experiment in a cohort of healthy young adults (
    MeSH term(s) Young Adult ; Humans ; Adult ; Incretins ; Glucose Tolerance Test ; Blood Glucose ; Healthy Volunteers ; C-Peptide ; Glucagon-Like Peptide 1 ; Insulin ; Glucose ; Gastric Inhibitory Polypeptide/physiology
    Chemical Substances Incretins ; Blood Glucose ; C-Peptide ; Glucagon-Like Peptide 1 (89750-14-1) ; Insulin ; Glucose (IY9XDZ35W2) ; Gastric Inhibitory Polypeptide (59392-49-3)
    Language English
    Publishing date 2023-09-13
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, U.S. Gov't, Non-P.H.S.
    ZDB-ID 603841-4
    ISSN 1522-1555 ; 0193-1849
    ISSN (online) 1522-1555
    ISSN 0193-1849
    DOI 10.1152/ajpendo.00104.2022
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: A look at duodenal mucosal resurfacing: Rationale for targeting the duodenum in type 2 diabetes.

    Hoyt, Jonah A / Cozzi, Emily / D'Alessio, David A / Thompson, Chris C / Aroda, Vanita R

    Diabetes, obesity & metabolism

    2024  

    Abstract: Affecting 5%-10% of the world population, type 2 diabetes (T2DM) is firmly established as one of the major health burdens of modern society. People with T2DM require long-term therapies to reduce blood glucose, an approach that can mitigate the vascular ... ...

    Abstract Affecting 5%-10% of the world population, type 2 diabetes (T2DM) is firmly established as one of the major health burdens of modern society. People with T2DM require long-term therapies to reduce blood glucose, an approach that can mitigate the vascular complications. However, fewer than half of those living with T2DM reach their glycaemic targets despite the availability of multiple oral and injectable medications. Adherence and access to medications are major barriers contributing to suboptimal diabetes treatment. The gastrointestinal tract has recently emerged as a target for treating T2DM and altering the underlying disease course. Preclinical and clinical analyses have elucidated changes in the mucosal layer of the duodenum potentially caused by dietary excess and obesity, which seem to be prevalent among individuals with metabolic disease. Supporting these findings, gastric bypass, a surgical procedure which removes the duodenum from the intestinal nutrient flow, has remarkable effects that improve, and often cause remission of, diabetes. From this perspective, we explore the rationale for targeting the duodenum with duodenal mucosal resurfacing (DMR). We examine the underlying physiology of the duodenum and its emerging role in T2DM pathogenesis, the rationale for targeting the duodenum by DMR as a potential treatment for T2DM, and current data surrounding DMR. Importantly, DMR has been demonstrated to change mucosal abnormalities common in those with obesity and diabetes. Given the multifactorial aetiology of T2DM, understanding proximate contributors to disease pathogenesis opens the door to rethinking therapeutic approaches to T2DM, from symptom management toward disease modification.
    Language English
    Publishing date 2024-03-04
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1454944-x
    ISSN 1463-1326 ; 1462-8902
    ISSN (online) 1463-1326
    ISSN 1462-8902
    DOI 10.1111/dom.15533
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Dissecting the Tumor Microenvironment to Predict Immunotherapy Response in Hepatocellular Cancer.

    D'Alessio, Antonio / Pinato, David J

    Gastroenterology

    2022  Volume 163, Issue 6, Page(s) 1712–1713

    MeSH term(s) Humans ; Carcinoma, Hepatocellular/therapy ; Liver Neoplasms/therapy ; Tumor Microenvironment ; Immunotherapy ; Immunologic Factors
    Chemical Substances Immunologic Factors
    Language English
    Publishing date 2022-08-11
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 80112-4
    ISSN 1528-0012 ; 0016-5085
    ISSN (online) 1528-0012
    ISSN 0016-5085
    DOI 10.1053/j.gastro.2022.08.024
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.

    Nauck, Michael A / D'Alessio, David A

    Cardiovascular diabetology

    2022  Volume 21, Issue 1, Page(s) 169

    Abstract: Tirzepatide is the first dual GIP/GLP-1 receptor co-agonist approved for the treatment of type 2 diabetes in the USA, Europe, and the UAE. Tirzepatide is an acylated peptide engineered to activate the GIP and GLP-1 receptors, key mediators of insulin ... ...

    Abstract Tirzepatide is the first dual GIP/GLP-1 receptor co-agonist approved for the treatment of type 2 diabetes in the USA, Europe, and the UAE. Tirzepatide is an acylated peptide engineered to activate the GIP and GLP-1 receptors, key mediators of insulin secretion that are also expressed in regions of the brain that regulate food intake. Five clinical trials in type 2-diabetic subjects (SURPASS 1-5) have shown that tirzepatide at 5-15 mg per week reduces both HbA
    MeSH term(s) Body Weight ; Cardiovascular Diseases/epidemiology ; Clinical Trials as Topic ; Diabetes Mellitus, Type 2/drug therapy ; Gastric Inhibitory Polypeptide/adverse effects ; Glucagon-Like Peptide 1/therapeutic use ; Glucagon-Like Peptide-1 Receptor/agonists ; Glycemic Control ; Humans ; Hypoglycemic Agents/adverse effects ; Insulin/therapeutic use ; Meta-Analysis as Topic ; Weight Loss
    Chemical Substances Glucagon-Like Peptide-1 Receptor ; Hypoglycemic Agents ; Insulin ; Gastric Inhibitory Polypeptide (59392-49-3) ; Glucagon-Like Peptide 1 (89750-14-1) ; tirzepatide (OYN3CCI6QE)
    Language English
    Publishing date 2022-09-01
    Publishing country England
    Document type Journal Article ; Review ; Research Support, Non-U.S. Gov't
    ZDB-ID 2093769-6
    ISSN 1475-2840 ; 1475-2840
    ISSN (online) 1475-2840
    ISSN 1475-2840
    DOI 10.1186/s12933-022-01604-7
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Slow and Steady Wins the Race: 25 Years Developing the GLP-1 Receptor as an Effective Target for Weight Loss.

    Kumar, Nitya / D'Alessio, David A

    The Journal of clinical endocrinology and metabolism

    2022  Volume 107, Issue 8, Page(s) 2148–2153

    Abstract: Recent evidence from clinical trials supports the efficacy and tolerability of glucagon-like peptide 1 (GLP-1) receptor agonists as useful agents for weight loss. Although originally developed as glucose lowering agents for people with type 2 diabetes, ... ...

    Abstract Recent evidence from clinical trials supports the efficacy and tolerability of glucagon-like peptide 1 (GLP-1) receptor agonists as useful agents for weight loss. Although originally developed as glucose lowering agents for people with type 2 diabetes, progress in research over the last 3 decades has demonstrated that GLP-1 receptor agonists act in the central nervous system to reduce food intake. This minireview summarizes key aspects of GLP-1 biology and the clinical studies supporting the utility of the GLP-1 receptor signaling system as a therapeutic target for weight loss.
    MeSH term(s) Diabetes Mellitus, Type 2/drug therapy ; Glucagon-Like Peptide 1/therapeutic use ; Glucagon-Like Peptide-1 Receptor/agonists ; Humans ; Hypoglycemic Agents/pharmacology ; Hypoglycemic Agents/therapeutic use ; Weight Loss
    Chemical Substances Glucagon-Like Peptide-1 Receptor ; Hypoglycemic Agents ; Glucagon-Like Peptide 1 (89750-14-1)
    Language English
    Publishing date 2022-05-10
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 3029-6
    ISSN 1945-7197 ; 0021-972X
    ISSN (online) 1945-7197
    ISSN 0021-972X
    DOI 10.1210/clinem/dgac276
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top